{"gene":"FOXP3","run_date":"2026-06-09T23:54:44","timeline":{"discoveries":[{"year":2001,"finding":"FOXP3 (Scurfin) requires its forkhead domain for nuclear localization and DNA binding. When transiently expressed in heterologous cells, FOXP3 represses transcription from a reporter containing multimeric forkhead binding sites. Overexpression in CD4+ T cells attenuates activation-induced cytokine production and proliferation. FKH binding sequences were identified adjacent to NFAT regulatory sites in promoters of cytokine genes sensitive to FOXP3 abundance.","method":"Transient transfection of heterologous cells with reporter assay, domain mutagenesis, overexpression in CD4+ T cells with cytokine/proliferation readouts","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct reporter assay with domain mutagenesis, functional readout in primary T cells, multiple orthogonal methods in one study","pmids":["11483607"],"is_preprint":false},{"year":2000,"finding":"Loss-of-function mutations in FOXP3 (JM2), including a splice junction mutation producing a truncated protein lacking the forkhead domain, and an in-frame 3-bp deletion predicted to impair a leucine zipper dimerization domain, cause X-linked autoimmunity-allergic dysregulation syndrome (XLAAD) with Th2 skewing and multi-system autoimmunity.","method":"Positional-candidate gene cloning, mutation identification in two kindreds, analysis of T cell phenotype","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct mutation identification with defined domain disruption; independently replicated in multiple kindreds; established founding mechanism for FOXP3 in immune tolerance","pmids":["11120765"],"is_preprint":false},{"year":2007,"finding":"Smad3 and NFAT are required for activity of a FOXP3 enhancer element, and both factors are essential for histone acetylation in the enhancer region and induction of FOXP3 expression. This was established using a model system with primary T cells and biochemical analysis of the enhancer.","method":"Enhancer reporter assay, chromatin immunoprecipitation for histone acetylation, primary T cell system with TGF-β stimulation","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — reporter assay plus ChIP for histone marks in primary T cells, multiple orthogonal methods in one study","pmids":["18157133"],"is_preprint":false},{"year":2009,"finding":"Runx proteins regulate both the initiation and maintenance of Foxp3 gene expression. Runx/core-binding factor beta binds regulatory elements within the Foxp3 locus. Full-length Runx promoted de novo Foxp3 expression during inducible Treg differentiation; a dominant-negative Runt DNA-binding domain antagonized de novo Foxp3 expression. Runx proteins and Foxp3 form a feed-forward loop in which Runx drives Foxp3 expression and then cooperates with Foxp3 protein to regulate downstream target genes.","method":"ChIP showing Runx/CBFβ binding at Foxp3 locus, dominant-negative Runt domain functional assay, inducible Treg differentiation assay","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ChIP plus functional domain assay in primary T cells, multiple orthogonal methods","pmids":["19841090"],"is_preprint":false},{"year":2016,"finding":"TET2 and TET3 enzymes mediate loss of 5-methylcytosine at Treg-specific hypomethylated regions including CNS1 and CNS2 of the Foxp3 locus during thymic Treg development, stabilizing Foxp3 expression. In Tet2/Tet3 double-deficient mice, stability of Foxp3 expression is markedly compromised, phenocopying CNS2-deficient Treg cells. Vitamin C potentiates TET activity through Tet2/Tet3 to increase Foxp3 stability in TGF-β-induced Tregs.","method":"Tet2/Tet3 double-knockout mice, bisulfite sequencing of Foxp3 CNS1/CNS2, vitamin C treatment with Foxp3 stability readout","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO with defined epigenetic readout and pharmacological rescue, multiple orthogonal methods","pmids":["26903244"],"is_preprint":false},{"year":2020,"finding":"A CRISPR-based pooled screen in primary mouse Tregs identified USP22 (a deubiquitination module member of the SAGA complex) as a positive regulator and RNF20 (an E3 ubiquitin ligase) as a negative regulator of Foxp3 expression. Treg-specific ablation of Usp22 reduced Foxp3 protein levels and caused suppressive function defects leading to spontaneous autoimmunity. Foxp3 destabilization in Usp22-deficient Tregs was rescued by ablation of Rnf20, revealing a reciprocal ubiquitin switch.","method":"CRISPR pooled screen in primary Tregs, Treg-specific Usp22 knockout mice, Rnf20/Usp22 double knockout rescue, in vivo autoimmunity and tumor growth models","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR screen plus genetic KO with epistasis rescue and multiple in vivo phenotypic readouts","pmids":["32499641"],"is_preprint":false},{"year":2023,"finding":"FOXP3 uses its forkhead domain to form higher-order multimers upon binding to TnG repeat microsatellites. Cryo-EM structure reveals a ladder-like architecture with two double-stranded DNA molecules as 'side rails' bridged by five pairs of FOXP3 molecules. Each FOXP3 subunit binds TGTTTGT within the repeats identically to binding the forkhead consensus motif (TGTTTAC). Mutations in the intra-rung interface impair TnG repeat recognition, DNA bridging, and cellular functions without affecting binding to the canonical forkhead motif. FOXP3 tolerates variable inter-rung spacings explaining broad in vivo specificity for TnG-repeat-like sequences.","method":"Cryo-EM structure determination, intra-rung interface mutagenesis, DNA binding assays in vitro and in vivo, cellular functional assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structure plus mutagenesis plus functional validation, multiple orthogonal methods in one study","pmids":["38030726"],"is_preprint":false},{"year":2017,"finding":"FOXP3 is both necessary and sufficient to program increased oxidative phosphorylation (OXPHOS) capacity and fatty acid oxidation in Tregs. Using metabolic analysis and proteomics, Foxp3 drives upregulation of components of all electron transport chain complexes, increasing their activity and ATP generation. This results in selective protection of Foxp3+ cells from fatty acid-induced cell death.","method":"Metabolic analysis (Seahorse), mass spectrometry-based proteomics, Foxp3 gain- and loss-of-function in T cells","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Moderate — necessity and sufficiency shown with multiple orthogonal methods (metabolic assay + proteomics + KO/OE) in one study","pmids":["28194435"],"is_preprint":false},{"year":2017,"finding":"FOXP3-mediated suppression in human Tregs requires physical interaction between FOXP3 and the histone acetyltransferase TIP60 (KAT5). The common IPEX mutation p.A384T abrogates the suppressive capacity of Tregs while preserving FOXP3's ability to repress inflammatory cytokine production. This selective functional impairment is due to specific disruption of FOXP3-A384T binding to TIP60. The defect can be corrected using allosteric modifiers that enhance FOXP3–TIP60 interaction.","method":"Patient-derived Treg cells with IPEX mutation characterization, co-immunoprecipitation of FOXP3–TIP60 interaction, suppression assays, allosteric modifier rescue","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — patient mutation analysis with Co-IP, functional suppression assay, and pharmacological rescue; multiple orthogonal methods","pmids":["28783662"],"is_preprint":false},{"year":2009,"finding":"HDAC inhibitor trichostatin A increases Foxp3+ Treg suppressive function at least in part by promoting acetylation of Foxp3 protein itself. Acetylation of Foxp3 is required for effective binding of Foxp3 to the IL-2 gene promoter and suppression of IL-2 expression. Class II HDAC activity (but not class I alone) is critical for this regulation.","method":"HDAC inhibitor treatment of Tregs, protein acetylation analysis, ChIP/promoter binding assay for IL-2 promoter, in vitro and in vivo suppression assays","journal":"Immunology and cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single lab, pharmacological approach with ChIP readout; mechanism inferred from inhibitor studies rather than direct deacetylase identification","pmids":["19172156"],"is_preprint":false},{"year":2020,"finding":"Deletion of HDAC10 in Tregs increases their suppressive function in vitro and in vivo. HDAC10-deficient Tregs protected Rag1-/- mice from colitis and conferred long-term allograft tolerance in fully MHC-mismatched cardiac transplants, whereas wild-type Tregs did not. This implicates HDAC10-mediated deacetylation as a negative regulator of Foxp3+ Treg suppressive function.","method":"HDAC10 knockout mice, adoptive transfer colitis model, cardiac allograft transplant model, in vitro suppression assay","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KO with defined cellular phenotype in multiple in vivo models; single lab","pmids":["31949209"],"is_preprint":false},{"year":2015,"finding":"Androgen receptor binds a functional androgen response element within the Foxp3 locus and modulates Foxp3 expression. AR binding leads to changes in acetylation status of histone H4 at the Foxp3 locus, while methylation of defined CpG regions in the Foxp3 gene is unaffected.","method":"ChIP for AR binding at Foxp3 locus, histone H4 acetylation analysis, CpG methylation analysis, functional androgen response element identification","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP evidence for AR binding with histone modification readout; single lab, limited replication","pmids":["26063731"],"is_preprint":false},{"year":2011,"finding":"FOXP3 directly suppresses SATB1 expression and induces miR-7 and miR-155, which target the 3'-UTR of SATB1, forming a feed-forward regulatory loop. This mechanism operates in breast cancer cells where FOXP3 acts as a tumor suppressor.","method":"Luciferase 3'-UTR reporter assay, miRNA expression analysis, FOXP3 overexpression/knockdown in breast cancer cells","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — 3'-UTR reporter assay and expression analysis; single lab, single cell type","pmids":["21743493"],"is_preprint":false},{"year":2016,"finding":"FOXP3 expressed in pancreatic ductal adenocarcinoma cancer cells directly trans-activates CCL5 transcription, promoting recruitment of FOXP3+ Treg cells to tumors. This recruitment was impaired by CCL5 neutralization and inhibited tumor growth.","method":"ChIP and luciferase reporter assay demonstrating direct FOXP3 binding to CCL5 promoter, in vitro migration assay, syngeneic mouse tumor models with CCL5 neutralization","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter assay plus in vivo functional readout; single lab","pmids":["27991933"],"is_preprint":false},{"year":2018,"finding":"FOXP3 directly binds the VEGF promoter via forkhead-binding motifs and suppresses VEGF transcription in breast cancer cells, thereby inhibiting angiogenesis.","method":"Luciferase reporter assay, ChIP demonstrating FOXP3 binding to VEGF promoter, FOXP3 overexpression in breast cancer cell lines, HUVEC tube formation assay","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter assay plus functional angiogenesis readout; single lab","pmids":["29970908"],"is_preprint":false},{"year":2015,"finding":"FOXP3 directly binds the CD44 promoter and represses its transcription in breast cancer cells, thereby suppressing adhesion, invasion, and metastasis. This was confirmed by luciferase reporter assay, ChIP, and electrophoretic mobility shift assay.","method":"Luciferase reporter assay, ChIP, EMSA, FOXP3 siRNA knockdown and overexpression in breast cancer cells, in vivo metastasis assay","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — three complementary DNA-binding assays plus functional in vivo readout; single lab","pmids":["25683728"],"is_preprint":false},{"year":2012,"finding":"FOXP3 acts as a transcriptional regulator of p21 and c-MYC in glioblastoma stem-like cells. ChIP demonstrated direct FOXP3 binding at p21 and c-MYC loci, supporting a mechanism by which FOXP3 loss de-represses these targets to promote tumorigenesis.","method":"ChIP for FOXP3 at p21 and c-MYC loci, FOXP3 knockdown and overexpression in glioblastoma neurosphere cells, proliferation and migration assays, xenograft model","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP with functional KD/OE readouts; single lab, single cell type","pmids":["23888189"],"is_preprint":false},{"year":2021,"finding":"MALAT1 (lncRNA) stabilizes FOXP3 protein by binding to the zinc finger (ZF) and leucine zipper (LZ) domains of FOXP3, masking the same domains used by E3 ligase STUB1 to interact with FOXP3. This prevents STUB1-mediated ubiquitination and degradation of FOXP3. FOXP3 in turn serves as a transcriptional activator of GINS1, defining a MALAT1-FOXP3-GINS1 regulatory axis.","method":"Co-immunoprecipitation of MALAT1 with FOXP3, domain mapping of FOXP3 interaction sites, STUB1-FOXP3 ubiquitination assay, FOXP3 ChIP at GINS1 promoter","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP domain mapping plus ubiquitination assay plus ChIP; single lab; lncRNA-protein interaction methods have inherent limitations","pmids":["33972684"],"is_preprint":false},{"year":2024,"finding":"Foxp3-chromatin binding is dynamically regulated by Treg activation states, tumor microenvironment, and antigen/cytokine stimulations. NFAT and AP-1 transcription factor Batf are required for enhanced Foxp3-chromatin binding in activated Tregs and tumor-infiltrating Tregs. Mutations at the Foxp3 DNA-binding domain destabilize Foxp3-chromatin association. Proteomics revealed dynamic protein interactions within Foxp3 proximity upon TCR or IL-2 receptor signaling, reflecting interactions among Foxp3, signal transducers, and chromatin.","method":"CUT&RUN/ChIP for Foxp3-chromatin binding under multiple activation conditions, proximity proteomics, pharmacological inhibition and genetic knockdown of NFAT and Batf, Foxp3 DNA-binding domain mutations","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal methods (chromatin binding assays, proximity proteomics, mutagenesis, pharmacological and genetic perturbation) in one study","pmids":["38935023"],"is_preprint":false},{"year":2024,"finding":"Lag3, an inhibitory co-receptor expressed on Tregs, supports Foxp3+ Treg suppressive function by restraining Myc-dependent metabolic programming. Treg-specific Lag3 mutation activated the PI3K-Akt-Rictor pathway, elevating Myc expression to levels seen in Th1 effector cells. Inhibition of PI3K, Rictor, or Ldha (a key Myc target) restored normal metabolism and suppressive function in Lag3-mutant Tregs.","method":"Treg cell-specific Lag3-mutant mouse models, RNA sequencing, metabolic profiling, pharmacological inhibition of PI3K/Rictor/Ldha, in vivo autoimmunity model","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic Treg-specific KO with RNA-seq, metabolic profiling, and pathway rescue; multiple orthogonal methods","pmids":["39236718"],"is_preprint":false},{"year":2022,"finding":"Genetic tracing of peripherally induced Treg cells showed that many distinguishing features of microbiota-induced pTreg cells are Foxp3-independent. Lineage-committed pTreg-like cells persisted in the colon without Foxp3. Foxp3 was critical for suppression of a Th17 cell program, colitis, and mastocytosis, but pTreg cells suppressed colonic effector T cell expansion in a Foxp3-independent manner.","method":"Genetic lineage tracing of microbiota-induced pTreg cells, Foxp3-deficient pTreg cell fate mapping, colitis and mastocytosis phenotypic readouts","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic tracing with multiple orthogonal in vivo phenotypic readouts distinguishing Foxp3-dependent vs -independent functions","pmids":["35700740"],"is_preprint":false}],"current_model":"FOXP3 is a forkhead transcription factor that forms higher-order multimers on TnG microsatellite repeats (cryo-EM structure established), acts as both a transcriptional repressor and activator by assembling dynamic chromatin-associated complexes (requiring TIP60/KAT5 interaction for suppressive function, and NFAT/Batf co-factors for activation-state-dependent chromatin binding), is regulated at the post-translational level by a USP22/RNF20 ubiquitin switch and by TET2/3-mediated demethylation of CNS1/CNS2 loci for stable expression, programs oxidative phosphorylation and fatty acid oxidation metabolism in Tregs, and is necessary (though not solely sufficient) for the suppressive identity of regulatory T cells—its loss causing fatal multi-organ autoimmunity via loss of Treg function, as defined by both human IPEX mutations and mouse genetic models."},"narrative":{"mechanistic_narrative":"FOXP3 is a forkhead-domain transcription factor that serves as the central determinant of regulatory T (Treg) cell suppressive identity, and whose loss-of-function mutations cause fatal X-linked multi-organ autoimmunity (XLAAD/IPEX) [PMID:11120765, PMID:32499641]. Through its forkhead domain it localizes to the nucleus, binds DNA, and represses transcription from forkhead-motif reporters [PMID:11483607], and it achieves much of its in vivo specificity by assembling higher-order multimers on TnG-repeat microsatellites: cryo-EM reveals a ladder-like architecture in which paired FOXP3 subunits bridge two DNA duplexes, an arrangement disrupted by intra-rung interface mutations that impair DNA bridging and cellular function without affecting canonical motif binding [PMID:38030726]. FOXP3 acts as both repressor and context-dependent activator by recruiting chromatin-modifying partners and signal-responsive co-factors; suppressive function specifically requires physical interaction with the acetyltransferase TIP60/KAT5, and the recurrent IPEX mutation p.A384T selectively abolishes TIP60 binding while sparing cytokine repression [PMID:28783662], whereas in activated and tumor-infiltrating Tregs enhanced FOXP3-chromatin binding depends on NFAT and the AP-1 factor Batf [PMID:38935023]. Beyond gene regulation, FOXP3 is both necessary and sufficient to program elevated oxidative phosphorylation and fatty acid oxidation, reprogramming Treg metabolism and protecting cells from lipid-induced death [PMID:28194435]. FOXP3 expression and protein stability are controlled by multiple layers: TET2/TET3-mediated demethylation of the CNS1/CNS2 elements stabilizes expression [PMID:26903244], Smad3/NFAT and Runx/CBFβ drive its induction and maintenance [PMID:18157133, PMID:19841090], and a reciprocal USP22/RNF20 ubiquitin switch sets FOXP3 protein levels, with USP22 loss causing destabilization and autoimmunity rescuable by RNF20 ablation [PMID:32499641]. Lineage-tracing demonstrates that FOXP3 is necessary for suppression of Th17 programs and colitis but is not solely sufficient for all peripheral Treg suppressive features [PMID:35700740].","teleology":[{"year":2000,"claim":"Establishing that FOXP3 mutations cause heritable autoimmunity defined the gene as a non-redundant guardian of immune tolerance and motivated all subsequent mechanistic work.","evidence":"Positional-candidate cloning and mutation identification in XLAAD kindreds, including a forkhead-truncating splice mutation and a leucine-zipper-disrupting deletion","pmids":["11120765"],"confidence":"High","gaps":["Did not define FOXP3's molecular activity or cellular mechanism of suppression","Causal cell type (Tregs) not yet established"]},{"year":2001,"claim":"First biochemical characterization showed FOXP3 is a forkhead-domain transcriptional repressor that dampens T cell activation, framing it as a negative regulator of effector responses.","evidence":"Reporter assays with domain mutagenesis in heterologous cells plus overexpression in primary CD4+ T cells with cytokine/proliferation readouts","pmids":["11483607"],"confidence":"High","gaps":["Endogenous target genes not identified","Did not address activator functions or cofactor requirements","Mechanism of repression unresolved"]},{"year":2007,"claim":"Identifying Smad3 and NFAT as enhancer-dependent inducers explained how TGF-β signaling installs FOXP3 expression during Treg differentiation.","evidence":"Enhancer reporter assays and ChIP for histone acetylation in TGF-β-stimulated primary T cells","pmids":["18157133"],"confidence":"High","gaps":["Did not address maintenance of expression after induction","Direct FOXP3 protein function not examined"]},{"year":2009,"claim":"Runx/CBFβ was shown to both initiate and maintain Foxp3 and to partner with FOXP3 protein, revealing a feed-forward loop linking induction to downstream gene control.","evidence":"ChIP of Runx/CBFβ at the Foxp3 locus plus dominant-negative Runt domain in inducible Treg differentiation","pmids":["19841090"],"confidence":"High","gaps":["Specific shared target genes of the Runx-FOXP3 complex not enumerated","Structural basis of cooperation unknown"]},{"year":2009,"claim":"Acetylation of FOXP3 protein itself was implicated in suppressive function, linking HDAC activity to FOXP3 promoter binding at IL-2.","evidence":"HDAC inhibitor (TSA) treatment of Tregs with FOXP3 acetylation and IL-2 promoter ChIP readouts","pmids":["19172156"],"confidence":"Medium","gaps":["Mechanism inferred from inhibitor studies rather than direct deacetylase identification","Specific acetylated residues not mapped"]},{"year":2011,"claim":"Cancer-cell studies extended FOXP3's role to tumor suppression via a miRNA feed-forward loop targeting SATB1.","evidence":"3'-UTR luciferase reporters and miRNA expression analysis with FOXP3 perturbation in breast cancer cells","pmids":["21743493"],"confidence":"Medium","gaps":["Single cell type, single lab","Relevance to Treg biology unclear"]},{"year":2012,"claim":"FOXP3 was shown to directly regulate proliferation genes (p21, c-MYC) in glioblastoma stem-like cells, supporting a context-dependent tumor-suppressive transcriptional program.","evidence":"ChIP at p21 and c-MYC loci with knockdown/overexpression and xenograft readouts","pmids":["23888189"],"confidence":"Medium","gaps":["Single cell type","Direct vs indirect regulation incompletely resolved"]},{"year":2015,"claim":"Hormonal and additional tumor-context studies (AR binding at Foxp3; CD44 repression) broadened the regulatory inputs and direct targets of FOXP3.","evidence":"ChIP for AR at the Foxp3 locus with histone H4 acetylation readout; luciferase/ChIP/EMSA for FOXP3 at CD44 with in vivo metastasis assay","pmids":["26063731","25683728"],"confidence":"Medium","gaps":["AR-FOXP3 axis limited to single lab","Physiological context of cancer-cell FOXP3 expression debated"]},{"year":2016,"claim":"TET2/TET3-mediated demethylation of CNS1/CNS2 was established as the epigenetic basis for stable FOXP3 expression, explaining heritable Treg lineage commitment.","evidence":"Tet2/Tet3 double-knockout mice with bisulfite sequencing of Foxp3 CNS regions and vitamin C pharmacological potentiation","pmids":["26903244"],"confidence":"High","gaps":["How demethylation is targeted to specific CNS elements not fully defined","Connection to upstream signaling incomplete"]},{"year":2016,"claim":"FOXP3 in pancreatic cancer cells was shown to trans-activate CCL5, illustrating an activator function that shapes the tumor immune microenvironment.","evidence":"ChIP/luciferase for FOXP3 at the CCL5 promoter plus migration and syngeneic tumor models with CCL5 neutralization","pmids":["27991933"],"confidence":"Medium","gaps":["Single lab","Cofactors enabling activation not defined"]},{"year":2017,"claim":"FOXP3 was shown to directly program Treg metabolism, reframing it as a driver of cellular energetics, not only transcription.","evidence":"Seahorse metabolic analysis and proteomics with FOXP3 gain- and loss-of-function in T cells","pmids":["28194435"],"confidence":"High","gaps":["Direct metabolic target genes not enumerated","Link between metabolic state and suppression mechanistically incomplete"]},{"year":2017,"claim":"Identifying the FOXP3-TIP60 interaction as essential for suppression separated FOXP3's suppressive function from its cytokine-repressive function and explained a recurrent IPEX mutation.","evidence":"Patient-derived Tregs carrying p.A384T, Co-IP of FOXP3-TIP60, suppression assays, and allosteric modifier rescue","pmids":["28783662"],"confidence":"High","gaps":["Genome-wide consequences of TIP60 recruitment not mapped","Structural detail of interface limited"]},{"year":2018,"claim":"Direct FOXP3 repression of VEGF connected its tumor-suppressive activity to angiogenesis control.","evidence":"ChIP/luciferase for FOXP3 at the VEGF promoter with HUVEC tube formation assay in breast cancer cells","pmids":["29970908"],"confidence":"Medium","gaps":["Single lab, single cancer type"]},{"year":2020,"claim":"A reciprocal USP22/RNF20 ubiquitin switch was defined as the post-translational rheostat setting FOXP3 protein abundance and Treg suppressive integrity.","evidence":"CRISPR pooled screen in primary Tregs, Treg-specific Usp22 knockout, and Rnf20/Usp22 double-knockout epistasis rescue with in vivo autoimmunity readouts","pmids":["32499641"],"confidence":"High","gaps":["Direct ubiquitination sites on FOXP3 not mapped here","How signaling tunes the switch unknown"]},{"year":2020,"claim":"HDAC10 was identified as a negative regulator of Treg suppressive function, extending acetylation-based control to in vivo tolerance.","evidence":"HDAC10 knockout mice in adoptive colitis and cardiac allograft tolerance models with in vitro suppression assays","pmids":["31949209"],"confidence":"Medium","gaps":["Direct FOXP3 acetylation substrate relationship not demonstrated","Single lab"]},{"year":2021,"claim":"lncRNA MALAT1 was shown to shield FOXP3 from STUB1-mediated degradation by competitive domain masking, adding an RNA-based layer of protein stabilization.","evidence":"Co-IP and domain mapping of MALAT1-FOXP3, STUB1 ubiquitination assay, and FOXP3 ChIP at GINS1","pmids":["33972684"],"confidence":"Medium","gaps":["lncRNA-protein interaction methods have inherent limitations","Single lab; physiological relevance in Tregs untested"]},{"year":2022,"claim":"Lineage tracing dissected FOXP3-dependent from FOXP3-independent peripheral Treg features, showing FOXP3 is necessary but not solely sufficient for all suppressive functions.","evidence":"Genetic lineage tracing and Foxp3-deficient pTreg fate mapping with colitis and mastocytosis readouts","pmids":["35700740"],"confidence":"High","gaps":["Identity of FOXP3-independent suppressive determinants unresolved","Molecular basis of FOXP3-independent persistence unknown"]},{"year":2023,"claim":"The cryo-EM structure of FOXP3 multimers on TnG repeats revealed a ladder-like DNA-bridging architecture, explaining its broad in vivo specificity and the functional cost of forkhead-interface mutations.","evidence":"Cryo-EM structure determination with intra-rung interface mutagenesis and in vitro/in vivo DNA-binding and cellular functional assays","pmids":["38030726"],"confidence":"High","gaps":["How multimer assembly is regulated in cells not addressed","Link between specific multimers and target gene choice unresolved"]},{"year":2024,"claim":"FOXP3 chromatin engagement was shown to be dynamically remodeled by activation state and microenvironment through NFAT/Batf, establishing a signal-responsive logic to its genomic occupancy.","evidence":"CUT&RUN/ChIP under multiple activation conditions, proximity proteomics, and genetic/pharmacological perturbation of NFAT and Batf","pmids":["38935023"],"confidence":"High","gaps":["Full proximity interactome not exhaustively defined","Causal link between dynamic binding and suppressive output incomplete"]},{"year":2024,"claim":"Lag3 was shown to restrain Myc-dependent metabolic reprogramming to preserve FOXP3+ Treg function, integrating co-receptor signaling with the metabolic program FOXP3 establishes.","evidence":"Treg-specific Lag3-mutant mice with RNA-seq, metabolic profiling, and PI3K/Rictor/Ldha pathway inhibition in an autoimmunity model","pmids":["39236718"],"confidence":"High","gaps":["Direct interplay between Lag3 signaling and FOXP3 protein not defined","How metabolic state feeds back on FOXP3 activity unclear"]},{"year":null,"claim":"How FOXP3 multimer composition, cofactor recruitment (TIP60, NFAT/Batf), post-translational switches, and metabolic programming are integrated into a single coherent gene-regulatory output remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No unified model linking structure-defined multimers to specific target gene selection","Mechanism coupling metabolic reprogramming to transcriptional output unknown","FOXP3-independent suppressive determinants in pTregs unidentified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,6,13,14,15,16,18]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,6,15]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[8,17]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[6,18]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,5,20]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,6,18]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[7,19]}],"complexes":[],"partners":["TIP60","NFAT","BATF","RUNX","CBFB","SMAD3","STUB1","MALAT1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9BZS1","full_name":"Forkhead box protein P3","aliases":["Scurfin"],"length_aa":431,"mass_kda":47.2,"function":"Transcriptional regulator which is crucial for the development and inhibitory function of regulatory T-cells (Treg) (PubMed:17377532, PubMed:21458306, PubMed:23947341, PubMed:24354325, PubMed:24722479, PubMed:24835996, PubMed:30513302, PubMed:32644293). Plays an essential role in maintaining homeostasis of the immune system by allowing the acquisition of full suppressive function and stability of the Treg lineage, and by directly modulating the expansion and function of conventional T-cells (PubMed:23169781). Can act either as a transcriptional repressor or a transcriptional activator depending on its interactions with other transcription factors, histone acetylases and deacetylases (PubMed:17377532, PubMed:21458306, PubMed:23947341, PubMed:24354325, PubMed:24722479). The suppressive activity of Treg involves the coordinate activation of many genes, including CTLA4 and TNFRSF18 by FOXP3 along with repression of genes encoding cytokines such as interleukin-2 (IL2) and interferon-gamma (IFNG) (PubMed:17377532, PubMed:21458306, PubMed:23947341, PubMed:24354325, PubMed:24722479). Inhibits cytokine production and T-cell effector function by repressing the activity of two key transcription factors, RELA and NFATC2 (PubMed:15790681). Mediates transcriptional repression of IL2 via its association with histone acetylase KAT5 and histone deacetylase HDAC7 (PubMed:17360565). Can activate the expression of TNFRSF18, IL2RA and CTLA4 and repress the expression of IL2 and IFNG via its association with transcription factor RUNX1 (PubMed:17377532). Inhibits the differentiation of IL17 producing helper T-cells (Th17) by antagonizing RORC function, leading to down-regulation of IL17 expression, favoring Treg development (PubMed:18368049). Inhibits the transcriptional activator activity of RORA (PubMed:18354202). Can repress the expression of IL2 and IFNG via its association with transcription factor IKZF4 (By similarity)","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q9BZS1/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FOXP3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FOXP3","total_profiled":1310},"omim":[{"mim_id":"618398","title":"T-CELL LYMPHOMA, SUBCUTANEOUS PANNICULITIS-LIKE; SPTCL","url":"https://www.omim.org/entry/618398"},{"mim_id":"618394","title":"IMMUNODEFICIENCY 60 AND AUTOIMMUNITY; IMD60","url":"https://www.omim.org/entry/618394"},{"mim_id":"616100","title":"IMMUNE DYSREGULATION WITH AUTOIMMUNITY, IMMUNODEFICIENCY, AND LYMPHOPROLIFERATION; IDAIL","url":"https://www.omim.org/entry/616100"},{"mim_id":"614700","title":"IMMUNODEFICIENCY, COMMON VARIABLE, 8, WITH AUTOIMMUNITY; CVID8","url":"https://www.omim.org/entry/614700"},{"mim_id":"614162","title":"IMMUNODEFICIENCY 31C; IMD31C","url":"https://www.omim.org/entry/614162"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"epididymis","ntpm":4.9},{"tissue":"lymphoid tissue","ntpm":6.6}],"url":"https://www.proteinatlas.org/search/FOXP3"},"hgnc":{"alias_symbol":["JM2","XPID","AIID","PIDX","DIETER","SCURFIN"],"prev_symbol":["IPEX"]},"alphafold":{"accession":"Q9BZS1","domains":[{"cath_id":"1.10.10.10","chopping":"333-420","consensus_level":"high","plddt":88.428,"start":333,"end":420}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BZS1","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BZS1-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BZS1-F1-predicted_aligned_error_v6.png","plddt_mean":56.72},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FOXP3","jax_strain_url":"https://www.jax.org/strain/search?query=FOXP3"},"sequence":{"accession":"Q9BZS1","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9BZS1.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9BZS1/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BZS1"}},"corpus_meta":[{"pmid":"16551248","id":"PMC_16551248","title":"FOXP3: of mice and men.","date":"2006","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16551248","citation_count":766,"is_preprint":false},{"pmid":"11120765","id":"PMC_11120765","title":"JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome.","date":"2000","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/11120765","citation_count":684,"is_preprint":false},{"pmid":"21488902","id":"PMC_21488902","title":"Regulatory T cells and Foxp3.","date":"2011","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/21488902","citation_count":661,"is_preprint":false},{"pmid":"18157133","id":"PMC_18157133","title":"Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer.","date":"2007","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18157133","citation_count":639,"is_preprint":false},{"pmid":"30784578","id":"PMC_30784578","title":"Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer.","date":"2019","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/30784578","citation_count":586,"is_preprint":false},{"pmid":"28757603","id":"PMC_28757603","title":"The regulation of immune tolerance by FOXP3.","date":"2017","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28757603","citation_count":451,"is_preprint":false},{"pmid":"11483607","id":"PMC_11483607","title":"Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11483607","citation_count":420,"is_preprint":false},{"pmid":"17575071","id":"PMC_17575071","title":"OX40 costimulation turns off Foxp3+ Tregs.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17575071","citation_count":331,"is_preprint":false},{"pmid":"19641188","id":"PMC_19641188","title":"Epigenetic mechanisms of regulation of Foxp3 expression.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19641188","citation_count":300,"is_preprint":false},{"pmid":"26903244","id":"PMC_26903244","title":"Control of Foxp3 stability through modulation of TET activity.","date":"2016","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26903244","citation_count":286,"is_preprint":false},{"pmid":"19500966","id":"PMC_19500966","title":"Plasticity of CD4(+) FoxP3(+) T cells.","date":"2009","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19500966","citation_count":263,"is_preprint":false},{"pmid":"26918796","id":"PMC_26918796","title":"From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation.","date":"2016","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26918796","citation_count":248,"is_preprint":false},{"pmid":"23219401","id":"PMC_23219401","title":"Differentiation and function of Foxp3(+) effector regulatory T cells.","date":"2012","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23219401","citation_count":217,"is_preprint":false},{"pmid":"32499641","id":"PMC_32499641","title":"CRISPR screen in regulatory T cells reveals modulators of Foxp3.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32499641","citation_count":201,"is_preprint":false},{"pmid":"31478130","id":"PMC_31478130","title":"Regulatory T Cells: the Many Faces of Foxp3.","date":"2019","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31478130","citation_count":190,"is_preprint":false},{"pmid":"27991933","id":"PMC_27991933","title":"Cancer-FOXP3 directly activated CCL5 to recruit FOXP3+Treg cells in pancreatic ductal adenocarcinoma.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27991933","citation_count":187,"is_preprint":false},{"pmid":"24722479","id":"PMC_24722479","title":"FOXP3 and scurfy: how it all began.","date":"2014","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24722479","citation_count":180,"is_preprint":false},{"pmid":"28194435","id":"PMC_28194435","title":"Foxp3 drives oxidative phosphorylation and protection from lipotoxicity.","date":"2017","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/28194435","citation_count":175,"is_preprint":false},{"pmid":"18430198","id":"PMC_18430198","title":"Foxp3 expression in human cancer cells.","date":"2008","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18430198","citation_count":172,"is_preprint":false},{"pmid":"26063731","id":"PMC_26063731","title":"Androgen receptor modulates Foxp3 expression in CD4+CD25+Foxp3+ regulatory T-cells.","date":"2015","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/26063731","citation_count":156,"is_preprint":false},{"pmid":"28290453","id":"PMC_28290453","title":"Suppressive IL-17A+Foxp3+ and ex-Th17 IL-17AnegFoxp3+ Treg cells are a source of tumour-associated Treg cells.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28290453","citation_count":154,"is_preprint":false},{"pmid":"15661028","id":"PMC_15661028","title":"FOXP3 acts as a rheostat of the immune response.","date":"2005","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/15661028","citation_count":153,"is_preprint":false},{"pmid":"19371792","id":"PMC_19371792","title":"FOXP3 and the regulation of Treg/Th17 differentiation.","date":"2009","source":"Microbes and infection","url":"https://pubmed.ncbi.nlm.nih.gov/19371792","citation_count":146,"is_preprint":false},{"pmid":"28396406","id":"PMC_28396406","title":"Flicr, a long noncoding RNA, modulates Foxp3 expression and autoimmunity.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28396406","citation_count":140,"is_preprint":false},{"pmid":"22170955","id":"PMC_22170955","title":"CD4(+)Foxp3(+) regulatory T cell therapy in transplantation.","date":"2011","source":"Journal of molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/22170955","citation_count":138,"is_preprint":false},{"pmid":"21081189","id":"PMC_21081189","title":"FOXP3 and RORγt: transcriptional regulation of Treg and Th17.","date":"2010","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21081189","citation_count":128,"is_preprint":false},{"pmid":"18317533","id":"PMC_18317533","title":"IPEX as a result of mutations in FOXP3.","date":"2007","source":"Clinical & developmental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18317533","citation_count":127,"is_preprint":false},{"pmid":"23329997","id":"PMC_23329997","title":"Advances in distinguishing natural from induced Foxp3(+) regulatory T cells.","date":"2013","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23329997","citation_count":126,"is_preprint":false},{"pmid":"20603315","id":"PMC_20603315","title":"PI3 kinase signalling blocks Foxp3 expression by sequestering Foxo factors.","date":"2010","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20603315","citation_count":124,"is_preprint":false},{"pmid":"26441996","id":"PMC_26441996","title":"FOXP3(+) Treg Cells and Gender Bias in Autoimmune Diseases.","date":"2015","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26441996","citation_count":122,"is_preprint":false},{"pmid":"20498631","id":"PMC_20498631","title":"Human FOXP3 and cancer.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20498631","citation_count":114,"is_preprint":false},{"pmid":"16243487","id":"PMC_16243487","title":"IPEX and FOXP3: clinical and research perspectives.","date":"2005","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/16243487","citation_count":113,"is_preprint":false},{"pmid":"17045841","id":"PMC_17045841","title":"Cell-surface IL-7 receptor expression facilitates the purification of FOXP3(+) regulatory T cells.","date":"2006","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17045841","citation_count":103,"is_preprint":false},{"pmid":"28296468","id":"PMC_28296468","title":"Foxp3+ Regulatory T Cell Expression of Keratinocyte Growth Factor Enhances Lung Epithelial Proliferation.","date":"2017","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28296468","citation_count":101,"is_preprint":false},{"pmid":"35689826","id":"PMC_35689826","title":"Human FOXP3 and tumour microenvironment.","date":"2022","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35689826","citation_count":99,"is_preprint":false},{"pmid":"23319295","id":"PMC_23319295","title":"ICOS controls Foxp3(+) regulatory T-cell expansion, maintenance and IL-10 production during helminth infection.","date":"2013","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23319295","citation_count":96,"is_preprint":false},{"pmid":"25684698","id":"PMC_25684698","title":"Development of thymic Foxp3(+) regulatory T cells: TGF-β matters.","date":"2015","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25684698","citation_count":95,"is_preprint":false},{"pmid":"29093649","id":"PMC_29093649","title":"IL-17A-Producing Foxp3+ Regulatory T Cells and Human Diseases.","date":"2017","source":"Immune network","url":"https://pubmed.ncbi.nlm.nih.gov/29093649","citation_count":88,"is_preprint":false},{"pmid":"19841090","id":"PMC_19841090","title":"Runx proteins regulate Foxp3 expression.","date":"2009","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19841090","citation_count":84,"is_preprint":false},{"pmid":"21743493","id":"PMC_21743493","title":"FOXP3 and FOXP3-regulated microRNAs suppress SATB1 in breast cancer cells.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21743493","citation_count":84,"is_preprint":false},{"pmid":"20429413","id":"PMC_20429413","title":"FOXP3 and its role in the immune system.","date":"2009","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/20429413","citation_count":82,"is_preprint":false},{"pmid":"16873058","id":"PMC_16873058","title":"FOXP3 and NFAT: partners in tolerance.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16873058","citation_count":81,"is_preprint":false},{"pmid":"33193456","id":"PMC_33193456","title":"The Many Functions of Foxp3+ Regulatory T Cells in the Intestine.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33193456","citation_count":80,"is_preprint":false},{"pmid":"30864147","id":"PMC_30864147","title":"Mechanisms of human FoxP3+ Treg cell development and function in health and disease.","date":"2019","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30864147","citation_count":79,"is_preprint":false},{"pmid":"29484183","id":"PMC_29484183","title":"Human FOXP3+ T regulatory cell heterogeneity.","date":"2018","source":"Clinical & translational immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29484183","citation_count":77,"is_preprint":false},{"pmid":"20087581","id":"PMC_20087581","title":"Foxp3(+) cell infiltration and granzyme B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma.","date":"2010","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/20087581","citation_count":77,"is_preprint":false},{"pmid":"23161624","id":"PMC_23161624","title":"Neuropeptides and neuropeptide receptors: drug targets, and peptide and non-peptide ligands: a tribute to Prof. Dieter Seebach.","date":"2012","source":"Chemistry & biodiversity","url":"https://pubmed.ncbi.nlm.nih.gov/23161624","citation_count":76,"is_preprint":false},{"pmid":"35700740","id":"PMC_35700740","title":"Genetic tracing reveals transcription factor Foxp3-dependent and Foxp3-independent functionality of peripherally induced Treg cells.","date":"2022","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/35700740","citation_count":75,"is_preprint":false},{"pmid":"19172156","id":"PMC_19172156","title":"Using histone deacetylase inhibitors to enhance Foxp3(+) regulatory T-cell function and induce allograft tolerance.","date":"2009","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19172156","citation_count":71,"is_preprint":false},{"pmid":"30830965","id":"PMC_30830965","title":"The role of FOXP3+ regulatory T cells in human autoimmune and inflammatory diseases.","date":"2019","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30830965","citation_count":68,"is_preprint":false},{"pmid":"22211994","id":"PMC_22211994","title":"Foxp3(+) regulatory T cells, immune stimulation and host defence against infection.","date":"2012","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22211994","citation_count":65,"is_preprint":false},{"pmid":"26679087","id":"PMC_26679087","title":"Characterization of Th17 and FoxP3(+) Treg Cells in Paediatric Psoriasis Patients.","date":"2016","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26679087","citation_count":64,"is_preprint":false},{"pmid":"16903909","id":"PMC_16903909","title":"FOXP3 ensembles in T-cell regulation.","date":"2006","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/16903909","citation_count":63,"is_preprint":false},{"pmid":"23313429","id":"PMC_23313429","title":"FOXP3: genetic and epigenetic implications for autoimmunity.","date":"2013","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/23313429","citation_count":62,"is_preprint":false},{"pmid":"30630091","id":"PMC_30630091","title":"The expression of FOXP3 and its role in human cancers.","date":"2019","source":"Biochimica et biophysica acta. Reviews on cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30630091","citation_count":60,"is_preprint":false},{"pmid":"19539651","id":"PMC_19539651","title":"Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human.","date":"2009","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/19539651","citation_count":60,"is_preprint":false},{"pmid":"31949209","id":"PMC_31949209","title":"HDAC10 deletion promotes Foxp3+ T-regulatory cell function.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31949209","citation_count":57,"is_preprint":false},{"pmid":"21752667","id":"PMC_21752667","title":"The molecular mechanisms of Foxp3 gene regulation.","date":"2011","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21752667","citation_count":56,"is_preprint":false},{"pmid":"29970908","id":"PMC_29970908","title":"FOXP3 inhibits angiogenesis by downregulating VEGF in breast cancer.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29970908","citation_count":55,"is_preprint":false},{"pmid":"22240298","id":"PMC_22240298","title":"Nature and nurture in Foxp3(+) regulatory T cell development, stability, and function.","date":"2011","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22240298","citation_count":55,"is_preprint":false},{"pmid":"25778793","id":"PMC_25778793","title":"The immunosuppressive enzyme IL4I1 promotes FoxP3(+) regulatory T lymphocyte differentiation.","date":"2015","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25778793","citation_count":52,"is_preprint":false},{"pmid":"21237521","id":"PMC_21237521","title":"FOXP3+ regulatory T cells: control of FOXP3 expression by pharmacological agents.","date":"2011","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/21237521","citation_count":51,"is_preprint":false},{"pmid":"28365195","id":"PMC_28365195","title":"Zebrafish FOXP3 is required for the maintenance of immune tolerance.","date":"2017","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28365195","citation_count":50,"is_preprint":false},{"pmid":"35401839","id":"PMC_35401839","title":"CD4+FoxP3+CD73+ regulatory T cell promotes cardiac healing post-myocardial infarction.","date":"2022","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/35401839","citation_count":49,"is_preprint":false},{"pmid":"28783662","id":"PMC_28783662","title":"Suppression by human FOXP3+ regulatory T cells requires FOXP3-TIP60 interactions.","date":"2017","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28783662","citation_count":49,"is_preprint":false},{"pmid":"26054541","id":"PMC_26054541","title":"RORγt(+)Foxp3(+) Cells are an Independent Bifunctional Regulatory T Cell Lineage and Mediate Crescentic GN.","date":"2015","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/26054541","citation_count":49,"is_preprint":false},{"pmid":"23468109","id":"PMC_23468109","title":"Foxp3(+) regulatory T cells in tuberculosis.","date":"2013","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/23468109","citation_count":48,"is_preprint":false},{"pmid":"26635807","id":"PMC_26635807","title":"Clinical Outlook for Type-1 and FOXP3(+) T Regulatory Cell-Based Therapy.","date":"2015","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26635807","citation_count":47,"is_preprint":false},{"pmid":"25683728","id":"PMC_25683728","title":"FOXP3 suppresses breast cancer metastasis through downregulation of CD44.","date":"2015","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25683728","citation_count":47,"is_preprint":false},{"pmid":"27466478","id":"PMC_27466478","title":"The Role of FOXP3 in Human Cancers.","date":"2016","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27466478","citation_count":46,"is_preprint":false},{"pmid":"31099612","id":"PMC_31099612","title":"Menopause and FOXP3+ Treg cell depletion eliminate female protection against T cell-mediated angiotensin II hypertension.","date":"2019","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31099612","citation_count":46,"is_preprint":false},{"pmid":"26085205","id":"PMC_26085205","title":"Ubiquitin-dependent regulation of Foxp3 and Treg function.","date":"2015","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/26085205","citation_count":45,"is_preprint":false},{"pmid":"18626575","id":"PMC_18626575","title":"FOXP3 and its partners: structural and biochemical insights into the regulation of FOXP3 activity.","date":"2008","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/18626575","citation_count":44,"is_preprint":false},{"pmid":"31551927","id":"PMC_31551927","title":"Foxp3+ Regulatory T Cells in Bone and Hematopoietic Homeostasis.","date":"2019","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31551927","citation_count":43,"is_preprint":false},{"pmid":"33972684","id":"PMC_33972684","title":"MALAT1 modulated FOXP3 ubiquitination then affected GINS1 transcription and drived NSCLC proliferation.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33972684","citation_count":42,"is_preprint":false},{"pmid":"20667622","id":"PMC_20667622","title":"Dexamethasone upregulates FOXP3 expression without increasing regulatory activity.","date":"2010","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/20667622","citation_count":41,"is_preprint":false},{"pmid":"19076349","id":"PMC_19076349","title":"Functional analysis of FOXP3.","date":"2008","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/19076349","citation_count":39,"is_preprint":false},{"pmid":"31798580","id":"PMC_31798580","title":"Stability and Maintenance of Foxp3+ Treg Cells in Non-lymphoid Microenvironments.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31798580","citation_count":36,"is_preprint":false},{"pmid":"23534211","id":"PMC_23534211","title":"Degradation of polycyclic aromatic hydrocarbons by Pseudomonas sp. JM2 isolated from active sewage sludge of chemical plant.","date":"2012","source":"Journal of environmental sciences (China)","url":"https://pubmed.ncbi.nlm.nih.gov/23534211","citation_count":36,"is_preprint":false},{"pmid":"23947341","id":"PMC_23947341","title":"The role of FOXP3 in regulating immune responses.","date":"2013","source":"International reviews of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23947341","citation_count":35,"is_preprint":false},{"pmid":"16890893","id":"PMC_16890893","title":"FoxP3: a genetic link between immunodeficiency and autoimmune diseases.","date":"2005","source":"Autoimmunity reviews","url":"https://pubmed.ncbi.nlm.nih.gov/16890893","citation_count":32,"is_preprint":false},{"pmid":"21122941","id":"PMC_21122941","title":"Transcriptional regulation of Foxp3 in regulatory T cells.","date":"2010","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/21122941","citation_count":32,"is_preprint":false},{"pmid":"30936873","id":"PMC_30936873","title":"Glucocorticoid Receptor-Deficient Foxp3+ Regulatory T Cells Fail to Control Experimental Inflammatory Bowel Disease.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30936873","citation_count":32,"is_preprint":false},{"pmid":"29420850","id":"PMC_29420850","title":"Chitotriosidase inhibits allergic asthmatic airways via regulation of TGF-β expression and Foxp3+ Treg cells.","date":"2018","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/29420850","citation_count":32,"is_preprint":false},{"pmid":"33021155","id":"PMC_33021155","title":"FoxP3, CTLA-4, and IDO in Canine Melanocytic Tumors.","date":"2020","source":"Veterinary pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33021155","citation_count":31,"is_preprint":false},{"pmid":"38030726","id":"PMC_38030726","title":"FOXP3 recognizes microsatellites and bridges DNA through multimerization.","date":"2023","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/38030726","citation_count":30,"is_preprint":false},{"pmid":"20515837","id":"PMC_20515837","title":"CD4 (+)CD25 (+)Foxp3 (+) regulatory T cells and hematologic malignancies.","date":"2010","source":"Frontiers in bioscience (Scholar edition)","url":"https://pubmed.ncbi.nlm.nih.gov/20515837","citation_count":30,"is_preprint":false},{"pmid":"36788428","id":"PMC_36788428","title":"Acidity-mediated induction of FoxP3+ regulatory T cells.","date":"2023","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36788428","citation_count":30,"is_preprint":false},{"pmid":"39236718","id":"PMC_39236718","title":"Inhibitory co-receptor Lag3 supports Foxp3+ regulatory T cell function by restraining Myc-dependent metabolic programming.","date":"2024","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/39236718","citation_count":29,"is_preprint":false},{"pmid":"22827571","id":"PMC_22827571","title":"Helios expression in FoxP3(+) T regulatory cells.","date":"2012","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/22827571","citation_count":29,"is_preprint":false},{"pmid":"33929751","id":"PMC_33929751","title":"Induction of stable human FOXP3+ Tregs by a parasite-derived TGF-β mimic.","date":"2021","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/33929751","citation_count":29,"is_preprint":false},{"pmid":"38211712","id":"PMC_38211712","title":"The FOXP3+ Pro-Inflammatory T Cell: A Potential Therapeutic Target in Crohn's Disease.","date":"2024","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/38211712","citation_count":28,"is_preprint":false},{"pmid":"25623530","id":"PMC_25623530","title":"Downregulation of FOXP3 inhibits invasion and immune escape in cholangiocarcinoma.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25623530","citation_count":28,"is_preprint":false},{"pmid":"27544816","id":"PMC_27544816","title":"The role of FOXP3 in autoimmunity.","date":"2016","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27544816","citation_count":27,"is_preprint":false},{"pmid":"34257746","id":"PMC_34257746","title":"Coexpression of Helios in Foxp3+ Regulatory T Cells and Its Role in Human Disease.","date":"2021","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/34257746","citation_count":27,"is_preprint":false},{"pmid":"32849510","id":"PMC_32849510","title":"IL-34 Actions on FOXP3+ Tregs and CD14+ Monocytes Control Human Graft Rejection.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32849510","citation_count":26,"is_preprint":false},{"pmid":"23888189","id":"PMC_23888189","title":"FOXP3, a novel glioblastoma oncosuppressor, affects proliferation and migration.","date":"2012","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/23888189","citation_count":25,"is_preprint":false},{"pmid":"30381008","id":"PMC_30381008","title":"FoxP3 and IDO in Canine Melanocytic Tumors.","date":"2018","source":"Veterinary pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30381008","citation_count":24,"is_preprint":false},{"pmid":"38935023","id":"PMC_38935023","title":"Dynamic Foxp3-chromatin interaction controls tunable Treg cell function.","date":"2024","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38935023","citation_count":23,"is_preprint":false},{"pmid":"35359918","id":"PMC_35359918","title":"Tissue Resident Foxp3+ Regulatory T Cells: Sentinels and Saboteurs in Health and Disease.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35359918","citation_count":23,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":42003,"output_tokens":5696,"usd":0.105724,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14227,"output_tokens":5762,"usd":0.107592,"stage2_stop_reason":"end_turn"},"total_usd":0.213316,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"FOXP3 (Scurfin) requires its forkhead domain for nuclear localization and DNA binding. When transiently expressed in heterologous cells, FOXP3 represses transcription from a reporter containing multimeric forkhead binding sites. Overexpression in CD4+ T cells attenuates activation-induced cytokine production and proliferation. FKH binding sequences were identified adjacent to NFAT regulatory sites in promoters of cytokine genes sensitive to FOXP3 abundance.\",\n      \"method\": \"Transient transfection of heterologous cells with reporter assay, domain mutagenesis, overexpression in CD4+ T cells with cytokine/proliferation readouts\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct reporter assay with domain mutagenesis, functional readout in primary T cells, multiple orthogonal methods in one study\",\n      \"pmids\": [\"11483607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Loss-of-function mutations in FOXP3 (JM2), including a splice junction mutation producing a truncated protein lacking the forkhead domain, and an in-frame 3-bp deletion predicted to impair a leucine zipper dimerization domain, cause X-linked autoimmunity-allergic dysregulation syndrome (XLAAD) with Th2 skewing and multi-system autoimmunity.\",\n      \"method\": \"Positional-candidate gene cloning, mutation identification in two kindreds, analysis of T cell phenotype\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct mutation identification with defined domain disruption; independently replicated in multiple kindreds; established founding mechanism for FOXP3 in immune tolerance\",\n      \"pmids\": [\"11120765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Smad3 and NFAT are required for activity of a FOXP3 enhancer element, and both factors are essential for histone acetylation in the enhancer region and induction of FOXP3 expression. This was established using a model system with primary T cells and biochemical analysis of the enhancer.\",\n      \"method\": \"Enhancer reporter assay, chromatin immunoprecipitation for histone acetylation, primary T cell system with TGF-β stimulation\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — reporter assay plus ChIP for histone marks in primary T cells, multiple orthogonal methods in one study\",\n      \"pmids\": [\"18157133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Runx proteins regulate both the initiation and maintenance of Foxp3 gene expression. Runx/core-binding factor beta binds regulatory elements within the Foxp3 locus. Full-length Runx promoted de novo Foxp3 expression during inducible Treg differentiation; a dominant-negative Runt DNA-binding domain antagonized de novo Foxp3 expression. Runx proteins and Foxp3 form a feed-forward loop in which Runx drives Foxp3 expression and then cooperates with Foxp3 protein to regulate downstream target genes.\",\n      \"method\": \"ChIP showing Runx/CBFβ binding at Foxp3 locus, dominant-negative Runt domain functional assay, inducible Treg differentiation assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ChIP plus functional domain assay in primary T cells, multiple orthogonal methods\",\n      \"pmids\": [\"19841090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TET2 and TET3 enzymes mediate loss of 5-methylcytosine at Treg-specific hypomethylated regions including CNS1 and CNS2 of the Foxp3 locus during thymic Treg development, stabilizing Foxp3 expression. In Tet2/Tet3 double-deficient mice, stability of Foxp3 expression is markedly compromised, phenocopying CNS2-deficient Treg cells. Vitamin C potentiates TET activity through Tet2/Tet3 to increase Foxp3 stability in TGF-β-induced Tregs.\",\n      \"method\": \"Tet2/Tet3 double-knockout mice, bisulfite sequencing of Foxp3 CNS1/CNS2, vitamin C treatment with Foxp3 stability readout\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with defined epigenetic readout and pharmacological rescue, multiple orthogonal methods\",\n      \"pmids\": [\"26903244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A CRISPR-based pooled screen in primary mouse Tregs identified USP22 (a deubiquitination module member of the SAGA complex) as a positive regulator and RNF20 (an E3 ubiquitin ligase) as a negative regulator of Foxp3 expression. Treg-specific ablation of Usp22 reduced Foxp3 protein levels and caused suppressive function defects leading to spontaneous autoimmunity. Foxp3 destabilization in Usp22-deficient Tregs was rescued by ablation of Rnf20, revealing a reciprocal ubiquitin switch.\",\n      \"method\": \"CRISPR pooled screen in primary Tregs, Treg-specific Usp22 knockout mice, Rnf20/Usp22 double knockout rescue, in vivo autoimmunity and tumor growth models\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR screen plus genetic KO with epistasis rescue and multiple in vivo phenotypic readouts\",\n      \"pmids\": [\"32499641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FOXP3 uses its forkhead domain to form higher-order multimers upon binding to TnG repeat microsatellites. Cryo-EM structure reveals a ladder-like architecture with two double-stranded DNA molecules as 'side rails' bridged by five pairs of FOXP3 molecules. Each FOXP3 subunit binds TGTTTGT within the repeats identically to binding the forkhead consensus motif (TGTTTAC). Mutations in the intra-rung interface impair TnG repeat recognition, DNA bridging, and cellular functions without affecting binding to the canonical forkhead motif. FOXP3 tolerates variable inter-rung spacings explaining broad in vivo specificity for TnG-repeat-like sequences.\",\n      \"method\": \"Cryo-EM structure determination, intra-rung interface mutagenesis, DNA binding assays in vitro and in vivo, cellular functional assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structure plus mutagenesis plus functional validation, multiple orthogonal methods in one study\",\n      \"pmids\": [\"38030726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FOXP3 is both necessary and sufficient to program increased oxidative phosphorylation (OXPHOS) capacity and fatty acid oxidation in Tregs. Using metabolic analysis and proteomics, Foxp3 drives upregulation of components of all electron transport chain complexes, increasing their activity and ATP generation. This results in selective protection of Foxp3+ cells from fatty acid-induced cell death.\",\n      \"method\": \"Metabolic analysis (Seahorse), mass spectrometry-based proteomics, Foxp3 gain- and loss-of-function in T cells\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — necessity and sufficiency shown with multiple orthogonal methods (metabolic assay + proteomics + KO/OE) in one study\",\n      \"pmids\": [\"28194435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FOXP3-mediated suppression in human Tregs requires physical interaction between FOXP3 and the histone acetyltransferase TIP60 (KAT5). The common IPEX mutation p.A384T abrogates the suppressive capacity of Tregs while preserving FOXP3's ability to repress inflammatory cytokine production. This selective functional impairment is due to specific disruption of FOXP3-A384T binding to TIP60. The defect can be corrected using allosteric modifiers that enhance FOXP3–TIP60 interaction.\",\n      \"method\": \"Patient-derived Treg cells with IPEX mutation characterization, co-immunoprecipitation of FOXP3–TIP60 interaction, suppression assays, allosteric modifier rescue\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — patient mutation analysis with Co-IP, functional suppression assay, and pharmacological rescue; multiple orthogonal methods\",\n      \"pmids\": [\"28783662\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"HDAC inhibitor trichostatin A increases Foxp3+ Treg suppressive function at least in part by promoting acetylation of Foxp3 protein itself. Acetylation of Foxp3 is required for effective binding of Foxp3 to the IL-2 gene promoter and suppression of IL-2 expression. Class II HDAC activity (but not class I alone) is critical for this regulation.\",\n      \"method\": \"HDAC inhibitor treatment of Tregs, protein acetylation analysis, ChIP/promoter binding assay for IL-2 promoter, in vitro and in vivo suppression assays\",\n      \"journal\": \"Immunology and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single lab, pharmacological approach with ChIP readout; mechanism inferred from inhibitor studies rather than direct deacetylase identification\",\n      \"pmids\": [\"19172156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Deletion of HDAC10 in Tregs increases their suppressive function in vitro and in vivo. HDAC10-deficient Tregs protected Rag1-/- mice from colitis and conferred long-term allograft tolerance in fully MHC-mismatched cardiac transplants, whereas wild-type Tregs did not. This implicates HDAC10-mediated deacetylation as a negative regulator of Foxp3+ Treg suppressive function.\",\n      \"method\": \"HDAC10 knockout mice, adoptive transfer colitis model, cardiac allograft transplant model, in vitro suppression assay\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO with defined cellular phenotype in multiple in vivo models; single lab\",\n      \"pmids\": [\"31949209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Androgen receptor binds a functional androgen response element within the Foxp3 locus and modulates Foxp3 expression. AR binding leads to changes in acetylation status of histone H4 at the Foxp3 locus, while methylation of defined CpG regions in the Foxp3 gene is unaffected.\",\n      \"method\": \"ChIP for AR binding at Foxp3 locus, histone H4 acetylation analysis, CpG methylation analysis, functional androgen response element identification\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP evidence for AR binding with histone modification readout; single lab, limited replication\",\n      \"pmids\": [\"26063731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"FOXP3 directly suppresses SATB1 expression and induces miR-7 and miR-155, which target the 3'-UTR of SATB1, forming a feed-forward regulatory loop. This mechanism operates in breast cancer cells where FOXP3 acts as a tumor suppressor.\",\n      \"method\": \"Luciferase 3'-UTR reporter assay, miRNA expression analysis, FOXP3 overexpression/knockdown in breast cancer cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — 3'-UTR reporter assay and expression analysis; single lab, single cell type\",\n      \"pmids\": [\"21743493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FOXP3 expressed in pancreatic ductal adenocarcinoma cancer cells directly trans-activates CCL5 transcription, promoting recruitment of FOXP3+ Treg cells to tumors. This recruitment was impaired by CCL5 neutralization and inhibited tumor growth.\",\n      \"method\": \"ChIP and luciferase reporter assay demonstrating direct FOXP3 binding to CCL5 promoter, in vitro migration assay, syngeneic mouse tumor models with CCL5 neutralization\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter assay plus in vivo functional readout; single lab\",\n      \"pmids\": [\"27991933\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FOXP3 directly binds the VEGF promoter via forkhead-binding motifs and suppresses VEGF transcription in breast cancer cells, thereby inhibiting angiogenesis.\",\n      \"method\": \"Luciferase reporter assay, ChIP demonstrating FOXP3 binding to VEGF promoter, FOXP3 overexpression in breast cancer cell lines, HUVEC tube formation assay\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter assay plus functional angiogenesis readout; single lab\",\n      \"pmids\": [\"29970908\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FOXP3 directly binds the CD44 promoter and represses its transcription in breast cancer cells, thereby suppressing adhesion, invasion, and metastasis. This was confirmed by luciferase reporter assay, ChIP, and electrophoretic mobility shift assay.\",\n      \"method\": \"Luciferase reporter assay, ChIP, EMSA, FOXP3 siRNA knockdown and overexpression in breast cancer cells, in vivo metastasis assay\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — three complementary DNA-binding assays plus functional in vivo readout; single lab\",\n      \"pmids\": [\"25683728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"FOXP3 acts as a transcriptional regulator of p21 and c-MYC in glioblastoma stem-like cells. ChIP demonstrated direct FOXP3 binding at p21 and c-MYC loci, supporting a mechanism by which FOXP3 loss de-represses these targets to promote tumorigenesis.\",\n      \"method\": \"ChIP for FOXP3 at p21 and c-MYC loci, FOXP3 knockdown and overexpression in glioblastoma neurosphere cells, proliferation and migration assays, xenograft model\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP with functional KD/OE readouts; single lab, single cell type\",\n      \"pmids\": [\"23888189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MALAT1 (lncRNA) stabilizes FOXP3 protein by binding to the zinc finger (ZF) and leucine zipper (LZ) domains of FOXP3, masking the same domains used by E3 ligase STUB1 to interact with FOXP3. This prevents STUB1-mediated ubiquitination and degradation of FOXP3. FOXP3 in turn serves as a transcriptional activator of GINS1, defining a MALAT1-FOXP3-GINS1 regulatory axis.\",\n      \"method\": \"Co-immunoprecipitation of MALAT1 with FOXP3, domain mapping of FOXP3 interaction sites, STUB1-FOXP3 ubiquitination assay, FOXP3 ChIP at GINS1 promoter\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP domain mapping plus ubiquitination assay plus ChIP; single lab; lncRNA-protein interaction methods have inherent limitations\",\n      \"pmids\": [\"33972684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Foxp3-chromatin binding is dynamically regulated by Treg activation states, tumor microenvironment, and antigen/cytokine stimulations. NFAT and AP-1 transcription factor Batf are required for enhanced Foxp3-chromatin binding in activated Tregs and tumor-infiltrating Tregs. Mutations at the Foxp3 DNA-binding domain destabilize Foxp3-chromatin association. Proteomics revealed dynamic protein interactions within Foxp3 proximity upon TCR or IL-2 receptor signaling, reflecting interactions among Foxp3, signal transducers, and chromatin.\",\n      \"method\": \"CUT&RUN/ChIP for Foxp3-chromatin binding under multiple activation conditions, proximity proteomics, pharmacological inhibition and genetic knockdown of NFAT and Batf, Foxp3 DNA-binding domain mutations\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal methods (chromatin binding assays, proximity proteomics, mutagenesis, pharmacological and genetic perturbation) in one study\",\n      \"pmids\": [\"38935023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Lag3, an inhibitory co-receptor expressed on Tregs, supports Foxp3+ Treg suppressive function by restraining Myc-dependent metabolic programming. Treg-specific Lag3 mutation activated the PI3K-Akt-Rictor pathway, elevating Myc expression to levels seen in Th1 effector cells. Inhibition of PI3K, Rictor, or Ldha (a key Myc target) restored normal metabolism and suppressive function in Lag3-mutant Tregs.\",\n      \"method\": \"Treg cell-specific Lag3-mutant mouse models, RNA sequencing, metabolic profiling, pharmacological inhibition of PI3K/Rictor/Ldha, in vivo autoimmunity model\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic Treg-specific KO with RNA-seq, metabolic profiling, and pathway rescue; multiple orthogonal methods\",\n      \"pmids\": [\"39236718\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Genetic tracing of peripherally induced Treg cells showed that many distinguishing features of microbiota-induced pTreg cells are Foxp3-independent. Lineage-committed pTreg-like cells persisted in the colon without Foxp3. Foxp3 was critical for suppression of a Th17 cell program, colitis, and mastocytosis, but pTreg cells suppressed colonic effector T cell expansion in a Foxp3-independent manner.\",\n      \"method\": \"Genetic lineage tracing of microbiota-induced pTreg cells, Foxp3-deficient pTreg cell fate mapping, colitis and mastocytosis phenotypic readouts\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic tracing with multiple orthogonal in vivo phenotypic readouts distinguishing Foxp3-dependent vs -independent functions\",\n      \"pmids\": [\"35700740\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FOXP3 is a forkhead transcription factor that forms higher-order multimers on TnG microsatellite repeats (cryo-EM structure established), acts as both a transcriptional repressor and activator by assembling dynamic chromatin-associated complexes (requiring TIP60/KAT5 interaction for suppressive function, and NFAT/Batf co-factors for activation-state-dependent chromatin binding), is regulated at the post-translational level by a USP22/RNF20 ubiquitin switch and by TET2/3-mediated demethylation of CNS1/CNS2 loci for stable expression, programs oxidative phosphorylation and fatty acid oxidation metabolism in Tregs, and is necessary (though not solely sufficient) for the suppressive identity of regulatory T cells—its loss causing fatal multi-organ autoimmunity via loss of Treg function, as defined by both human IPEX mutations and mouse genetic models.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FOXP3 is a forkhead-domain transcription factor that serves as the central determinant of regulatory T (Treg) cell suppressive identity, and whose loss-of-function mutations cause fatal X-linked multi-organ autoimmunity (XLAAD/IPEX) [#1, #5]. Through its forkhead domain it localizes to the nucleus, binds DNA, and represses transcription from forkhead-motif reporters [#0], and it achieves much of its in vivo specificity by assembling higher-order multimers on TnG-repeat microsatellites: cryo-EM reveals a ladder-like architecture in which paired FOXP3 subunits bridge two DNA duplexes, an arrangement disrupted by intra-rung interface mutations that impair DNA bridging and cellular function without affecting canonical motif binding [#6]. FOXP3 acts as both repressor and context-dependent activator by recruiting chromatin-modifying partners and signal-responsive co-factors; suppressive function specifically requires physical interaction with the acetyltransferase TIP60/KAT5, and the recurrent IPEX mutation p.A384T selectively abolishes TIP60 binding while sparing cytokine repression [#8], whereas in activated and tumor-infiltrating Tregs enhanced FOXP3-chromatin binding depends on NFAT and the AP-1 factor Batf [#18]. Beyond gene regulation, FOXP3 is both necessary and sufficient to program elevated oxidative phosphorylation and fatty acid oxidation, reprogramming Treg metabolism and protecting cells from lipid-induced death [#7]. FOXP3 expression and protein stability are controlled by multiple layers: TET2/TET3-mediated demethylation of the CNS1/CNS2 elements stabilizes expression [#4], Smad3/NFAT and Runx/CBF\\u03b2 drive its induction and maintenance [#2, #3], and a reciprocal USP22/RNF20 ubiquitin switch sets FOXP3 protein levels, with USP22 loss causing destabilization and autoimmunity rescuable by RNF20 ablation [#5]. Lineage-tracing demonstrates that FOXP3 is necessary for suppression of Th17 programs and colitis but is not solely sufficient for all peripheral Treg suppressive features [#20].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Establishing that FOXP3 mutations cause heritable autoimmunity defined the gene as a non-redundant guardian of immune tolerance and motivated all subsequent mechanistic work.\",\n      \"evidence\": \"Positional-candidate cloning and mutation identification in XLAAD kindreds, including a forkhead-truncating splice mutation and a leucine-zipper-disrupting deletion\",\n      \"pmids\": [\"11120765\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define FOXP3's molecular activity or cellular mechanism of suppression\", \"Causal cell type (Tregs) not yet established\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"First biochemical characterization showed FOXP3 is a forkhead-domain transcriptional repressor that dampens T cell activation, framing it as a negative regulator of effector responses.\",\n      \"evidence\": \"Reporter assays with domain mutagenesis in heterologous cells plus overexpression in primary CD4+ T cells with cytokine/proliferation readouts\",\n      \"pmids\": [\"11483607\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous target genes not identified\", \"Did not address activator functions or cofactor requirements\", \"Mechanism of repression unresolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identifying Smad3 and NFAT as enhancer-dependent inducers explained how TGF-\\u03b2 signaling installs FOXP3 expression during Treg differentiation.\",\n      \"evidence\": \"Enhancer reporter assays and ChIP for histone acetylation in TGF-\\u03b2-stimulated primary T cells\",\n      \"pmids\": [\"18157133\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address maintenance of expression after induction\", \"Direct FOXP3 protein function not examined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Runx/CBF\\u03b2 was shown to both initiate and maintain Foxp3 and to partner with FOXP3 protein, revealing a feed-forward loop linking induction to downstream gene control.\",\n      \"evidence\": \"ChIP of Runx/CBF\\u03b2 at the Foxp3 locus plus dominant-negative Runt domain in inducible Treg differentiation\",\n      \"pmids\": [\"19841090\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific shared target genes of the Runx-FOXP3 complex not enumerated\", \"Structural basis of cooperation unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Acetylation of FOXP3 protein itself was implicated in suppressive function, linking HDAC activity to FOXP3 promoter binding at IL-2.\",\n      \"evidence\": \"HDAC inhibitor (TSA) treatment of Tregs with FOXP3 acetylation and IL-2 promoter ChIP readouts\",\n      \"pmids\": [\"19172156\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism inferred from inhibitor studies rather than direct deacetylase identification\", \"Specific acetylated residues not mapped\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Cancer-cell studies extended FOXP3's role to tumor suppression via a miRNA feed-forward loop targeting SATB1.\",\n      \"evidence\": \"3'-UTR luciferase reporters and miRNA expression analysis with FOXP3 perturbation in breast cancer cells\",\n      \"pmids\": [\"21743493\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cell type, single lab\", \"Relevance to Treg biology unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"FOXP3 was shown to directly regulate proliferation genes (p21, c-MYC) in glioblastoma stem-like cells, supporting a context-dependent tumor-suppressive transcriptional program.\",\n      \"evidence\": \"ChIP at p21 and c-MYC loci with knockdown/overexpression and xenograft readouts\",\n      \"pmids\": [\"23888189\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cell type\", \"Direct vs indirect regulation incompletely resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Hormonal and additional tumor-context studies (AR binding at Foxp3; CD44 repression) broadened the regulatory inputs and direct targets of FOXP3.\",\n      \"evidence\": \"ChIP for AR at the Foxp3 locus with histone H4 acetylation readout; luciferase/ChIP/EMSA for FOXP3 at CD44 with in vivo metastasis assay\",\n      \"pmids\": [\"26063731\", \"25683728\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"AR-FOXP3 axis limited to single lab\", \"Physiological context of cancer-cell FOXP3 expression debated\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"TET2/TET3-mediated demethylation of CNS1/CNS2 was established as the epigenetic basis for stable FOXP3 expression, explaining heritable Treg lineage commitment.\",\n      \"evidence\": \"Tet2/Tet3 double-knockout mice with bisulfite sequencing of Foxp3 CNS regions and vitamin C pharmacological potentiation\",\n      \"pmids\": [\"26903244\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How demethylation is targeted to specific CNS elements not fully defined\", \"Connection to upstream signaling incomplete\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"FOXP3 in pancreatic cancer cells was shown to trans-activate CCL5, illustrating an activator function that shapes the tumor immune microenvironment.\",\n      \"evidence\": \"ChIP/luciferase for FOXP3 at the CCL5 promoter plus migration and syngeneic tumor models with CCL5 neutralization\",\n      \"pmids\": [\"27991933\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Cofactors enabling activation not defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"FOXP3 was shown to directly program Treg metabolism, reframing it as a driver of cellular energetics, not only transcription.\",\n      \"evidence\": \"Seahorse metabolic analysis and proteomics with FOXP3 gain- and loss-of-function in T cells\",\n      \"pmids\": [\"28194435\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct metabolic target genes not enumerated\", \"Link between metabolic state and suppression mechanistically incomplete\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identifying the FOXP3-TIP60 interaction as essential for suppression separated FOXP3's suppressive function from its cytokine-repressive function and explained a recurrent IPEX mutation.\",\n      \"evidence\": \"Patient-derived Tregs carrying p.A384T, Co-IP of FOXP3-TIP60, suppression assays, and allosteric modifier rescue\",\n      \"pmids\": [\"28783662\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide consequences of TIP60 recruitment not mapped\", \"Structural detail of interface limited\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Direct FOXP3 repression of VEGF connected its tumor-suppressive activity to angiogenesis control.\",\n      \"evidence\": \"ChIP/luciferase for FOXP3 at the VEGF promoter with HUVEC tube formation assay in breast cancer cells\",\n      \"pmids\": [\"29970908\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, single cancer type\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"A reciprocal USP22/RNF20 ubiquitin switch was defined as the post-translational rheostat setting FOXP3 protein abundance and Treg suppressive integrity.\",\n      \"evidence\": \"CRISPR pooled screen in primary Tregs, Treg-specific Usp22 knockout, and Rnf20/Usp22 double-knockout epistasis rescue with in vivo autoimmunity readouts\",\n      \"pmids\": [\"32499641\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ubiquitination sites on FOXP3 not mapped here\", \"How signaling tunes the switch unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"HDAC10 was identified as a negative regulator of Treg suppressive function, extending acetylation-based control to in vivo tolerance.\",\n      \"evidence\": \"HDAC10 knockout mice in adoptive colitis and cardiac allograft tolerance models with in vitro suppression assays\",\n      \"pmids\": [\"31949209\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct FOXP3 acetylation substrate relationship not demonstrated\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"lncRNA MALAT1 was shown to shield FOXP3 from STUB1-mediated degradation by competitive domain masking, adding an RNA-based layer of protein stabilization.\",\n      \"evidence\": \"Co-IP and domain mapping of MALAT1-FOXP3, STUB1 ubiquitination assay, and FOXP3 ChIP at GINS1\",\n      \"pmids\": [\"33972684\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"lncRNA-protein interaction methods have inherent limitations\", \"Single lab; physiological relevance in Tregs untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Lineage tracing dissected FOXP3-dependent from FOXP3-independent peripheral Treg features, showing FOXP3 is necessary but not solely sufficient for all suppressive functions.\",\n      \"evidence\": \"Genetic lineage tracing and Foxp3-deficient pTreg fate mapping with colitis and mastocytosis readouts\",\n      \"pmids\": [\"35700740\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of FOXP3-independent suppressive determinants unresolved\", \"Molecular basis of FOXP3-independent persistence unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"The cryo-EM structure of FOXP3 multimers on TnG repeats revealed a ladder-like DNA-bridging architecture, explaining its broad in vivo specificity and the functional cost of forkhead-interface mutations.\",\n      \"evidence\": \"Cryo-EM structure determination with intra-rung interface mutagenesis and in vitro/in vivo DNA-binding and cellular functional assays\",\n      \"pmids\": [\"38030726\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How multimer assembly is regulated in cells not addressed\", \"Link between specific multimers and target gene choice unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"FOXP3 chromatin engagement was shown to be dynamically remodeled by activation state and microenvironment through NFAT/Batf, establishing a signal-responsive logic to its genomic occupancy.\",\n      \"evidence\": \"CUT&RUN/ChIP under multiple activation conditions, proximity proteomics, and genetic/pharmacological perturbation of NFAT and Batf\",\n      \"pmids\": [\"38935023\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full proximity interactome not exhaustively defined\", \"Causal link between dynamic binding and suppressive output incomplete\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Lag3 was shown to restrain Myc-dependent metabolic reprogramming to preserve FOXP3+ Treg function, integrating co-receptor signaling with the metabolic program FOXP3 establishes.\",\n      \"evidence\": \"Treg-specific Lag3-mutant mice with RNA-seq, metabolic profiling, and PI3K/Rictor/Ldha pathway inhibition in an autoimmunity model\",\n      \"pmids\": [\"39236718\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct interplay between Lag3 signaling and FOXP3 protein not defined\", \"How metabolic state feeds back on FOXP3 activity unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How FOXP3 multimer composition, cofactor recruitment (TIP60, NFAT/Batf), post-translational switches, and metabolic programming are integrated into a single coherent gene-regulatory output remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No unified model linking structure-defined multimers to specific target gene selection\", \"Mechanism coupling metabolic reprogramming to transcriptional output unknown\", \"FOXP3-independent suppressive determinants in pTregs unidentified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 6, 13, 14, 15, 16, 18]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 6, 15]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [8, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [6, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 5, 20]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 6, 18]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [7, 19]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TIP60\", \"NFAT\", \"BATF\", \"RUNX\", \"CBFB\", \"SMAD3\", \"STUB1\", \"MALAT1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}